Christopher B Roberts

US Patent:

7171311, Jan 30, 2007

Filed:

Jan 15, 2003

Appl. No.:

10/342887

Inventors:

Hongyue Dai - Bothell WA, US
Yudong He - Kirkland WA, US
Peter S. Linsley - Seattle WA, US
Mao Mao - Kirkland WA, US
Christopher J. Roberts - Seattle WA, US
Laura Johanna Van't Veer - Amsterdam, NL
Marc J. Van de Vijver - Amsterdam, NL
Rene Bernards - Abcoude, NL
A. A. M. Hart - Castricum, NL

Assignee:

Rosetta Inpharmatics LLC - Seattle WA
Netherlands Cancer Institute - Amsterdam

International Classification:

G01N 33/48
C12Q 1/68

US Classification:

702 19, 702 20, 702 23, 435 6, 435600

Abstract:

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also provides methods of classifying and treating patients based on prognosis. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the diagnostic, prognostic and statistical methods disclosed herein.

US Patent:

7514209, Apr 7, 2009

Filed:

Jun 14, 2002

Appl. No.:

10/172118

Inventors:

HongYue Dai - Bothell WA, US
Yudong He - Kirkland WA, US
Peter S. Linsley - Seattle WA, US
Mao Mao - Kirkland WA, US
Christopher J. Roberts - Seattle WA, US
Laura Johanna Van't Veer - Amsterdam, NL
Marc J. Van de Vijver - Amsterdam, NL
Rene Bernards - Abcoude, NL
Augustinus A. M. Hart - Steenwijk, NL

Assignee:

Rosetta Inpharmatics LLC - Seattle WA
The Netherlands Cancer Institute - Amsterdam

International Classification:

C12Q 1/68
G01N 33/48
C07H 21/00

US Classification:

435 6, 702 19, 536 231

Abstract:

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

US Patent:

7863001, Jan 4, 2011

Filed:

Jun 23, 2008

Appl. No.:

12/214878

Inventors:

HongYue Dai - Bothell WA, US
Yudong He - Kirkland WA, US
Peter S. Linsley - Seattle WA, US
Mao Mao - Kirkland WA, US
Christopher J. Roberts - Seattle WA, US
Laura Johanna Van't Veer - Amsterdam, NL
Marc J. Van de Vijver - Amsterdam, NL
Rene Bernards - Abcoude, NL
Augustinus A. M. Hart - Steenwijk, NL

Assignee:

The Netherlands Cancer Institute - Amsterdam
Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12Q 1/68
G01N 33/48
C07H 21/00

US Classification:

435 6, 702 19, 536 231

Abstract:

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

US Patent:

20030036930, Feb 20, 2003

Filed:

Aug 17, 2001

Appl. No.:

09/932268

Inventors:

Tomas Matos - Sammamish WA, US
Steve Murch - Seattle WA, US
Maja Bogdanovic - Seattle WA, US
Eric Monsowitz - Seattle WA, US
Lloyd Frink - Seattle WA, US
Christopher Roberts - Seattle WA, US

Assignee:

Expedia, Inc.

International Classification:

G06F017/60

US Classification:

705/005000

Abstract:

The present invention relates in general to on-line transportation reservation processing and, in particular, to a system and method for identifying and purchasing travel packages on-line. In one embodiment, package components are retrieved by a package server in response to a query from a consumer. A best package component is identified from the retrieved package components. Then a listing of packages matching the best package component is depicted for the consumer with real-time prices to the consumer. In another embodiment of the present invention, real-time prices corresponding to travel packages are related to published fares for package components. The relationship is calculated to maximize the real-time price relative to the price for published fares for the travel components. In still another embodiment of the present invention, travel packages are cross-sold to consumers when they are seeking to purchase a travel component that may be included in a travel package.

US Patent:

20030211475, Nov 13, 2003

Filed:

Sep 5, 2001

Appl. No.:

09/946290

Inventors:

Christopher Roberts - Seattle WA, US

Assignee:

Rosetta Inpharmatics, Inc.

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/006000, 702/020000

Abstract:

The present invention relates to methods for identifying one or more reporter genes for a particular biological pathway of interest. The reporter genes of this invention are particularly useful for analyzing the activity of particular biological pathways of interest, and may be further used in the design of drugs, drug therapies or other biological agents (e.g., insecticides, herbicides, fungicides, antibiotics, or antivirals) to target a particular biological pathway. The present invention also relates to methods for identifying one or more target genes for a particular biological pathway of interest. Target genes of the invention are useful as specific targets for drugs which may be designed to enhance, inhibit, or modulate a particular biological pathway. Methods to identify genes which modify the function or structure of a member (e.g., compound or gene product) of a particular biological pathway are provided.

US Patent:

20110301048, Dec 8, 2011

Filed:

Nov 23, 2010

Appl. No.:

12/953314

Inventors:

HongYue Dai - Bothell WA, US
Yudong He - Kirkland WA, US
Peter S. Linsley - Seattle WA, US
Mao Mao - Kirkland WA, US
Christopher J. Roberts - Seattle WA, US
Laura Johanna Van't Veer - Amsterdam, NL
Marc J. Van de Vijver - Amsterdam, NL
Rene Bernards - Abcoude, NL
A.A. M. Hart - Castricum, NL

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ
THE NETHERLANDS CANCER INSTITUTE - Amsterdam

International Classification:

C40B 30/02
C40B 40/06
C40B 30/04

US Classification:

506 8, 506 9, 506 16

Abstract:

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

US Patent:

20130116145, May 9, 2013

Filed:

Oct 19, 2012

Appl. No.:

13/656568

Inventors:

The Netherlands Cancer Institute - Amsterdam, NL
Peter S. Linsley - Seattle WA, US
Mao Mao - Kirkland WA, US
Christopher J. Roberts - Seattle WA, US
Laura Johanna Van't Veer - Amsterdam, NL
Marc J. Van de Vijver - Amsterdam, NL
Rene Bernards - Abcoude, NL
A.A. M. Hart - Castricum, NL

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ
THE NETHERLANDS CANCER INSTITUTE - Amsterdam

International Classification:

C12Q 1/68

US Classification:

506 9, 506 16

Abstract:

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

US Patent:

61975176, Mar 6, 2001

Filed:

May 21, 1999

Appl. No.:

9/315794

Inventors:

Christopher J. Roberts - Seattle WA

Assignee:

Rosetta Inpharmatics, Inc. - Kirkland WA

International Classification:

C12Q 168
C12N 1500
C12N 115
C12N 1511
C07H 2104

US Classification:

435 6

Abstract:

The present invention relates to genes in Saccharomyces cerevisiae which are essential for germination and proliferation of S. cerevisiae and using the identified genes or their encoded proteins as targets for highly specific antifungal agents, insecticides, herbicides and anti-proliferation drugs. The present invention provides antisense molecules and ribozymes comprising sequences complementary to the sequences of mRNAs of essential genes that function to inhibit the essential genes. The present invention also provides neutralizing antibodies to proteins encoded by essential genes that bind to and inactivate the essential gene products. The present invention further provides pharmaceutical compositions for treating fungal and proliferative diseases, as well as methods of treatment of fungal and proliferative diseases.